GEMCITABINE-DOCETAXEL VERSUS CISPLATIN-GEMCITABINE AS FIRST-LINE THERAPY IN PATIENTS WITH METASTATIC NON-SMALL-CELL LUNG CANCER

被引：0
|
作者：
Al-Gizawy, S. M. [1 ]
Mostafa, H. G. [1 ]
机构：
[1] Assiut Univ, Dept Clin Oncol, Fac Med, Assiut, Egypt
来源：
EUROPEAN JOURNAL OF CANCER | 2014年 / 50卷
关键词：
D O I：
10.1016/j.ejca.2014.03.065
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P0021
引用
收藏
页码：E15 / E15
页数：1
相关论文
共 50 条
  • [31] Economic analysis of TORCH: Erlotinib versus cisplatin and gemcitabine as first-line therapy for advanced non-small cell lung cancer (NSCLC).
    Chung, Carmen
    Isaranuwatchai, Wanrudee
    Di Maio, Massimo
    Jiang, Haiyan
    Lau, Anthea
    Hoch, Jeffrey S.
    Feld, Ronald
    Tsao, Ming Sound
    Gridelli, Cesare
    Ciardiello, Fortunato
    Butts, Charles Andrew
    Gallo, Ciro
    Perrone, Francesco
    Leighl, Natasha B.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [32] ECONOMIC ANALYSIS OF TORCH: ERLOTINIB VERSUS CISPLATIN AND GEMCITABINE AS FIRST-LINE THERAPY FOR ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)
    Chung, Carmen
    Jiang, Haiyan
    Isaranuwatchai, Wanrudee
    Di Maio, Mas-Simo
    Lau, Anthea
    Hoch, Jeffrey
    Feld, Ronald
    Tsao, Ming-Sound
    Gridelli, Cesare
    Gallo, Ciro
    Ciardiello, Fortunato
    Butts, Charles A.
    Perrone, Francesco
    Leighl, Natasha B.
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S602 - S603
  • [33] A phase II study of sequential docetaxel and gemcitabine followed by docetaxel and carboplatin as first-line therapy for non-small cell lung cancer
    Eleni M. Karapanagiotou
    Adrianni Charpidou
    Ifigenia Tzannou
    Kalliopi Dilana
    Elias Kotteas
    Ioannis Tourkantonis
    Epaminondas Kosmas
    Aspasia Provata
    Kostas Syrigos
    Medical Oncology, 2008, 25 : 303 - 308
  • [34] A phase II study of sequential docetaxel and gemcitabine followed by docetaxel and carboplatin as first-line therapy for non-small cell lung cancer
    Karapanagiotou, Eleni M.
    Charpidou, Adrianni
    Tzannou, Ifigenia
    Dilana, Kalliopi
    Kotteas, Elias
    Tourkantonis, Ioannis
    Kosmas, Epaminondas
    Provata, Aspasia
    Syrigos, Kostas
    MEDICAL ONCOLOGY, 2008, 25 (03) : 303 - 308
  • [35] Randomized multicenter phase II study of gemcitabine versus docetaxel as first-line therapy with second-line crossover in advanced-stage non-small-cell lung cancer
    Manegold, Christian
    Pilz, Lothar Richard
    Koschel, Gabriele
    Roemer, Katrin Schott-von
    Mezger, Joerg
    Hruska, Dagmar
    Dornof, Wolfgang
    Gosse, Helga
    Gatzemeier, Ulrich
    CLINICAL LUNG CANCER, 2005, 7 (03) : 208 - 214
  • [36] Randomized, Phase III Study of Gemcitabine or Erlotinib Maintenance Therapy Versus Observation, With Predefined Second-Line Treatment, After Cisplatin-Gemcitabine Induction Chemotherapy in Advanced Non-Small-Cell Lung Cancer
    Perol, Maurice
    Chouaid, Christos
    Perol, David
    Barlesi, Fabrice
    Gervais, Radj
    Westeel, Virginie
    Crequit, Jacky
    Lena, Herve
    Vergnenegre, Alain
    Zalcman, Gerard
    Monnet, Isabelle
    Le Caer, Herve
    Fournel, Pierre
    Falchero, Lionel
    Poudenx, Michel
    Vaylet, Fabien
    Segura-Ferlay, Celine
    Devouassoux-Shisheboran, Mojgan
    Taron, Miquel
    Milleron, Bernard
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (28) : 3516 - 3524
  • [37] PHASE I FEASIBILITY TRIAL ON A BIWEEKLY SCHEDULE OF CARBOPLATIN AND GEMCITABINE AS FIRST-LINE CHEMOTHERAPY IN PATIENTS WITH METASTATIC NON-SMALL-CELL LUNG CANCER
    Mancuso, Andrea
    Migliorino, Maria Rita
    Martelli, Olga
    Belli, Raffaele
    Di Molfetta, Michele
    De Petris, Luigi
    Di Salvia, Roberto
    De Marinis, Filippo
    ANNALS OF ONCOLOGY, 2004, 15 : 29 - 29
  • [38] Phase III Trial of Cisplatin Plus Gemcitabine With Either Placebo or Bevacizumab As First-Line Therapy for Nonsquamous Non-Small-Cell Lung Cancer: AVAiL
    Reck, Martin
    von Pawel, Joachim
    Zatloukal, Petr
    Ramlau, Rodryg
    Gorbounova, Vera
    Hirsh, Vera
    Leighl, Natasha
    Mezger, Joerg
    Archer, Venice
    Moore, Nicola
    Manegold, Christian
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (08) : 1227 - 1234
  • [39] Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer
    Sandler, AB
    Nemunaitis, J
    Denham, C
    von Pawel, J
    Cormier, Y
    Gatzemeier, U
    Mattson, K
    Manegold, C
    Palmer, MC
    Gregor, A
    Nguyen, B
    Niyikiza, C
    Einhorn, LH
    JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (01) : 122 - 130
  • [40] Efficacy and safety of pemetrexed/cisplatin versus gemcitabine/cisplatin as first-line treatment in Chinese patients with advanced nonsquamous non-small cell lung cancer
    Wu, Yi-Long
    Lu, Shun
    Cheng, Ying
    Zhou, Caicun
    Wang, Mengzhao
    Qin, Shukui
    Lu, You
    Zhang, Yang
    Zhu, Yunzhong
    Song, Xiangqun
    Wang, Xin
    Barraclough, Helen
    Zhang, Xiaoqing
    Chi, Haidong
    Orlando, Mauro
    LUNG CANCER, 2014, 85 (03) : 401 - 407
12345